Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARDINAL HEALTH INCCAH · Entity 3014 | Director | November 11, 2021 | November 15, 2021 |
| Solventum CorpSOLV · Entity 1645 | Director | May 15, 2026 | May 18, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | December 29, 2017 | August 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARDINAL HEALTH INC
Report date November 11, 2021 · Filed November 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 11,138 |
Reported balance
After 2021-11-11 transaction · row 1
1 source rowRow 1 · 2021-11-11 · Grant · Acquired 3,709 · Balance 11,138 F1: Grant of restricted share units that will vest on November 11, 2022, except if the 2022 Annual Meeting of Shareholders is prior to November 11, 2022, then the restricted share units will vest on the date of the 2022 Annual Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted share units that will vest on November 11, 2022, except if the 2022 Annual Meeting of Shareholders is prior to November 11, 2022, then the restricted share units will vest on the date of the 2022 Annual Meeting of Shareholders.
Solventum Corp
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,300 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 3,300 · Balance 3,300 F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.
WEST PHARMACEUTICAL SERVICES INC
Report date December 29, 2017 · Filed August 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitSEC Table II · derivative / convertible security | Direct | 24,627.5326 |
Reported balance
After 2017-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-29 · Grant · Acquired 260.5786 · Balance 24,627.5326 F2: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. |
| Common StockSEC Table I · non-derivative | Direct | 43,726.2341 |
Reported balance
Holding disclosure · report date 2017-12-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 43,726.2341 F1: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.
F2: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BARD C R INC /NJ/
Report date December 29, 2017 · Filed January 03, 2018
Section 16 reporting ended · disclosed 2018-01-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,719.29 |
Reported balance
After 2017-12-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-12-29 · Grant · Acquired 29,823 · Balance 72,719.29 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger. F2: Includes 29,823 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units. |
| Common StockSEC Table I · non-derivative | Direct | 83,977.29 |
Reported balance
After 2017-12-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-12-29 · Grant · Acquired 11,258 · Balance 83,977.29 F3: Includes 11,258 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger. |
| Common StockSEC Table I · non-derivative | Direct | 83,977 |
Reported balance
After 2017-12-29 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-12-29 · Disposition to issuer · Disposed 0.29 · Balance 83,977 F4: Includes 0.29 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | Direct | 66,952 |
Reported balance
After 2017-12-29 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2017-12-29 · Disposition to issuer · Disposed 17,025 · Balance 66,952 F5: Includes 17,025 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units. |
| Common StockSEC Table I · non-derivative | Direct | 37,129 |
Reported balance
After 2017-12-29 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2017-12-29 · Disposition to issuer · Disposed 29,823 · Balance 37,129 F2: Includes 29,823 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2017-12-29 · Disposition to issuer · Disposed 37,129 · Balance 0 F6: Includes 37,129 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 0 |
Reported balance
After 2017-12-29 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2017-12-29 · Disposition to issuer · Disposed 6,018.306 · Balance 0 F7: Includes 6,018.306 shares of Bard common stock held through the Bard 401(k) Plan that were disposed of upon the closing of the Merger. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $186.43 · Expires 2025-12-09 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-12-29 · Disposition to issuer · Disposed 29,855 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $168.87 · Expires 2024-12-10 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-12-29 · Disposition to issuer · Disposed 32,022 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $136.37 · Expires 2023-12-11 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-12-29 · Disposition to issuer · Disposed 11,145 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $219.56 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-12-29 · Disposition to issuer · Disposed 23,088 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger.
F2: Includes 29,823 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
F3: Includes 11,258 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger.
F4: Includes 0.29 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.
F5: Includes 17,025 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.
F6: Includes 37,129 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit.
F7: Includes 6,018.306 shares of Bard common stock held through the Bard 401(k) Plan that were disposed of upon the closing of the Merger.
F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 5,575 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.98 · Expires 2028-02-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 1,454 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: This option was fully exercisable.
F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2017 Filed Feb 10, 2017 18:23 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | SaleCommon Stock | 200 | $239.98 | $47,996.00 |
DisclosureSEC source: 0001225208-17-002829 · doc4.xml · nonDerivative · entry 6 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,212.29 F5 · kind: Sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 18:23 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | Tax withholdingCommon Stock | 11,136 | $236.68 | $2,635,668.48 |
DisclosureSEC source: 0001225208-17-002829 · doc4.xml · nonDerivative · entry 5 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,412.29 F4 · kind: Shares withheld to pay taxes upon vesting of performance-based restricted stock units granted under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 18:23 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 1,844 | $164.84 | $303,970.49 |
DisclosureSEC source: 0001225208-17-002829 · doc4.xml · nonDerivative · entry 4 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,548.29 F3 · kind: Restricted stock units acquired through deferral of compensation under the Company's Management Stock Purchase Program. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 18:23 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 4,303 | $235.49 | $1,013,313.47 |
DisclosureSEC source: 0001225208-17-002829 · doc4.xml · nonDerivative · entry 3 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,704.29 F3 · kind: Restricted stock units acquired through deferral of compensation under the Company's Management Stock Purchase Program. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 18:23 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 6,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-002829 · doc4.xml · nonDerivative · entry 2 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,401.29 F2 · price: Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated), 50% of which vest immediately and the remaining 50% vest in two equal annual installments on February 8, 2018 and February 8, 2019. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 18:23 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 22,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-002829 · doc4.xml · nonDerivative · entry 1 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,613.29 F1 · price: Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 19:57 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 264.0845 | $85.20 | $22,500.00 |
DisclosureSEC source: 0001562180-17-000147 · primarydocument.xml · derivative · entry 2 WEILAND JOHN H · CIK 0001204663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,514.546 Underlying: Common Stock · 264.0845 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 15:35 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantOption (Right to Buy) · Derivative | 23,088 | $0.00 Strike: $219.56 | $0.00 |
DisclosureSEC source: 0001225208-16-043398 · doc4.xml · derivative · entry 1 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,088 Underlying: Common Stock · 23,088 shares Expires 2026-12-14 F1 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F2 · derivative.exercise_date: Options vest in four equal annual installments beginning on December 14, 2017. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 12:10 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | Exercise / conversionOption (Right to Buy) · Derivative | 11,190 | $0.00 Strike: $97.69 | $0.00 |
DisclosureSEC source: 0001225208-16-043154 · doc4.xml · derivative · entry 7 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,190 shares Expires 2022-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F8 · derivative.exercise_date: Options fully vested and are currently exercisable. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 12:10 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | SaleCommon Stock | 7,418 | $219.67 | $1,629,496.48 |
DisclosureSEC source: 0001225208-16-043154 · doc4.xml · nonDerivative · entry 5 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,590.29 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F5 · price: Represents the weighted average sales price for price increments ranging from $219.16 to $220.15. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 12:10 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | SaleCommon Stock | 2,422 | $220.35 | $533,691.09 |
DisclosureSEC source: 0001225208-16-043154 · doc4.xml · nonDerivative · entry 4 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,008.29 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F4 · price: Represents the weighted average sales price for price increments ranging from $220.17 to $220.77. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 12:10 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | SaleCommon Stock | 1,000 | $218.82 | $218,824.10 |
DisclosureSEC source: 0001225208-16-043154 · doc4.xml · nonDerivative · entry 3 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,430.29 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F3 · price: Represents the weighted average sales price for price increments ranging from $218.12 to $219.10. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 12:10 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | SaleCommon Stock | 350 | $217.28 | $76,046.50 |
DisclosureSEC source: 0001225208-16-043154 · doc4.xml · nonDerivative · entry 2 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,430.29 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F2 · price: Represents the weighted average sales price for price increments ranging from $217.05 to $217.81. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 12:10 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | Exercise / conversionCommon Stock | 11,190 | $97.69 | $1,093,095.15 |
DisclosureSEC source: 0001225208-16-043154 · doc4.xml · nonDerivative · entry 1 WEILAND JOHN H · CIK 0001204663 · Director · Vice Chairman, Pres. and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,780.29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 19:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 303.5618 | $74.12 | $22,500.00 |
DisclosureSEC source: 0001225208-16-039977 · doc4.xml · derivative · entry 1 WEILAND JOHN H · CIK 0001204663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,176.1364 Underlying: Common Stock · 303.5618 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.